Supernus Pharmaceuticals (NASDAQ:SUPN) PT Set at $50.00 by Cowen

Cowen set a $50.00 target price on Supernus Pharmaceuticals (NASDAQ:SUPN) in a research report released on Wednesday, TipRanks reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald set a $60.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, May 8th. Stifel Nicolaus set a $55.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a buy rating in a report on Wednesday. Mizuho reiterated a buy rating on shares of Supernus Pharmaceuticals in a report on Wednesday. Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, July 17th. Finally, BidaskClub upgraded shares of Supernus Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. Supernus Pharmaceuticals presently has an average rating of Buy and a consensus price target of $54.43.

SUPN stock traded down $0.27 during trading on Wednesday, reaching $28.39. The stock had a trading volume of 682,711 shares, compared to its average volume of 505,890. Supernus Pharmaceuticals has a 1-year low of $27.59 and a 1-year high of $51.38. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.72 and a quick ratio of 2.59. The firm has a market capitalization of $1.50 billion, a P/E ratio of 14.70, a P/E/G ratio of 0.97 and a beta of 1.54. The company has a fifty day moving average of $32.02.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.05. Supernus Pharmaceuticals had a net margin of 25.66% and a return on equity of 22.36%. The firm had revenue of $104.70 million for the quarter, compared to analyst estimates of $109.67 million. During the same quarter in the previous year, the business posted $0.57 EPS. The firm’s revenue was up 5.2% compared to the same quarter last year. On average, research analysts expect that Supernus Pharmaceuticals will post 2.2 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Patriot Financial Group Insurance Agency LLC bought a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth about $33,000. Financial Gravity Wealth Inc. bought a new stake in shares of Supernus Pharmaceuticals in the 1st quarter worth about $44,000. Advisor Group Inc. increased its position in shares of Supernus Pharmaceuticals by 17.2% in the 4th quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 306 shares during the last quarter. Bremer Bank National Association bought a new stake in shares of Supernus Pharmaceuticals in the 1st quarter worth about $94,000. Finally, Huntington National Bank increased its position in shares of Supernus Pharmaceuticals by 881.4% in the 1st quarter. Huntington National Bank now owns 4,485 shares of the specialty pharmaceutical company’s stock worth $157,000 after purchasing an additional 4,028 shares during the last quarter. 99.29% of the stock is owned by institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Featured Story: Economic Bubble

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.